- Amended Annual Report (Small Business Issuers) (10KSB/A)
18 Dezembro 2008 - 8:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
10-KSB/A
Amendment
No. 1 to Form 10-KSB
x
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For the
fiscal year ended December 31, 2007
o
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the
transition period from _______ to ________
Commission
File Number:
000-17119
QUANTRX BIOMEDICAL
CORPORATION
(Name of
small business issuer in its charter)
Nevada
(State
or other jurisdiction of
incorporation
or organization)
|
33-0202574
(IRS
Employer Identification
No.)
|
100 South Main Street, Suite
300, Doylestown, Pennsylvania 18901
(Address
of principal executive offices) (Zip code)
(267)
880-1595
(Issuer’s
telephone number)
Securities
registered under Section 12(b) of the Exchange Act:
None
Securities
Registered Pursuant to Section 12(g) of the Exchange Act
Common Stock, $0.01 par
value
(Title of
class)
Check
whether the issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.
x
Yes
o
No
Check if
there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB.
o
Indicate
by a check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Act). Yes
o
No
x
State
issuer’s revenues for its most recent fiscal year: $747,119
At March
17, 2008 the aggregate market value of the common stock held by non-affiliates
of the issuer was approximately $28,683,303 based upon the closing price of
$0.82 reported for such date.
The
number of shares outstanding of the issuer’s common stock as of March 17, 2008
was 41,699,681.
Transitional
Small Business Disclosure Form (Check one): Yes
o
No
x
Explanatory
Note:
This
Amendment No. 1 to the Company’s Form 10-KSB filed on March 31, 2008 for the
year ended December 31, 2007 is being filed to revise certain language contained
in the certifications attached as Exhibits 31.1 and 31.2 to the original Form
10-KSB. This Amendment No. 1 contains only the exhibits to the
original Form 10-KSB that are being amended. The exhibits to the Form 10-KSB as
originally filed which are not included herein are unchanged and continue in
full force and effect as originally filed. This Amendment No. 1 speaks as
of the date of the original filing of the Form 10-KSB and has not been updated
to reflect events occurring subsequent to the original filing date.
Item
13. Exhibits
The
following exhibits are filed as part of this amended annual report:
31.1
|
|
Certification
of Principal Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002
|
31.2
|
|
Certification
of Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of
2002
|
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
QuantRx
Biomedical Corporation
|
|
|
Date: December
18, 2008
|
By:
|
/
s/ Walter W. Witoshkin
|
|
Walter
W. Witoshkin, Chairman & CEO
|
|
|
|
|
Date: December
18, 2008
|
By:
|
/s/ Sasha
Afanassiev
|
|
Sasha
Afanassiev, CFO, Treasurer & VP of
Finance
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.
|
QuantRx
Biomedical Corporation
|
|
|
Date: December
18, 2008
|
By:
|
/s/ Walter W. Witoshkin
|
|
Walter
W. Witoshkin, Director
|
|
|
|
|
Date: December
18, 2008
|
By:
|
/s/ William H. Fleming
|
|
William
H. Fleming, Director
|
|
|
|
|
Date: December
18, 2008
|
By:
|
/s/ Shalom Hirschman
|
|
Shalom
Hirschman, Director
|
QuantRx Biomedical (CE) (USOTC:QTXB)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
QuantRx Biomedical (CE) (USOTC:QTXB)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024